UiPath's Mixed Q2 and Raised FY27 Sales Guidance Do Not Yet Confirm Thesis Inflection

What happened

UiPath reported mixed results for its fiscal second quarter and raised its full-year sales guidance, according to Benzinga. The mixed nature suggests that while some metrics may have exceeded expectations, others likely fell short, possibly including ARR or net-new ARR, which are critical to the DeepValue thesis. The raised sales guidance could reflect stronger revenue recognition or renewed confidence in demand, but without specific numbers, it is premature to conclude that the agentic automation pivot is translating into durable growth. Investors should recall that the DeepValue report set clear checkpoints for this quarter: ARR within $1.929B–$1.934B, NRR above 108%, and RPO growth from $1.413B. Until the 10-Q filing confirms these metrics, the stock's recent volatility may continue as the market digests the ambiguous signal.

Implication

Over the next 6–12 months, UiPath's valuation will depend on whether the raised sales guidance translates into sustained ARR growth above 12% and NRR holding at or above 108%. If the Q2 10-Q shows ARR within the guided range and RPO growing, the base case of $12.50 and bull case of $16 become more credible, supporting a buy on dips near $10. However, if mixed results include deteriorating NRR or weak net-new ARR, the bear case of $8 gains prominence, and the stock could re-rate down despite the company's $1.4B liquidity and buybacks. Competitive bundling pressure from Microsoft and other suite vendors remains a persistent risk that could erode pricing power and expansion. Investors should monitor the next two quarterly reports for evidence that the agentic automation strategy is monetizing as management claims.

Thesis delta

The prior thesis was a POTENTIAL BUY based on Q1 FY27's 17% revenue growth and 109% NRR, with expectations for continued strength in Q2. The mixed Q2 results and raised sales guidance introduce uncertainty: while the sales raise is positive, the mixed nature implies some metrics missed, potentially weakening the conviction in near-term acceleration. The thesis remains intact but should be considered contingent on the upcoming 10-Q confirming ARR growth and NRR stability.